[12] Patent
[11] Patent No.:GC0007528  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125720
Date of the Decision to Grant the Patent:05/Apr/2018

[21] Application No.:GC 2011-18753

[22] Filing Date:5/7/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
6/7/2010
61/361,589

[72] Inventors:1- Nigel Graham Cooke،2- Paulo Fernandes Gomes Dos Santos،3- Nadege Graveleau،4- Christina Hebach،5- Klemens Hogenauer،6- Gregory Hollingworth،7- Alexander Baxter Smith،8- Nicolas Soldermann،9- Frank Stowasser،10- Ross Strang،11- Nicola Tufilli،12- Anette Von Matt،13- Romain Wolf،14- Frederic Zecri

[73] Owner: Novartis AG, Lichtstrasse 35, 4056, Basel, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/519; A61K 31/5377; C07D 471/04 (2006.01)

[56] Cited Documents:

-WO 2008/130481 A1 (RENOVJS INC [US]; WEI ZHI-LIANG [US]; DUNCTON NATTHEW ALEXANDER JANES) 30 October 2008
-WO 2006/119504 A2 (RENOVIS INC [US]; KELLY MICHAEL G [US]; KINCAID JOHN [US]; KAUB CARL J) 09 November 2006
 
Examiner: PH. Nada M. AlBehaiji

[54] TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES
[57] Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description.Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
No. of claims: 31


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.